Parkinson's Disease: Symptoms, Causes, Diagnosis, and Treatment

What is Parkinson’s Disease?

Parkinson’s disease is a chronic, progressive degenerative disorder of the central nervous system. It was first described in 1817 by British physician James Parkinson, who published An Essay on the Shaking Palsy, detailing the hallmark features of the condition that would later bear his name.

Parkinson’s disease represents a significant and growing global health burden, with millions of people affected worldwide. As the risk of developing Parkinson’s disease increases with age, the global number of cases is expected to rise sharply in parallel with the aging of the population.

Parkinson’s disease belongs to the broader group of movement disorders, and its four cardinal motor symptoms are:

• Tremor: an involuntary, rhythmic shaking of the hands, arms, legs, jaw, or head.
• Rigidity: stiffness of the limbs and trunk
• Bradykinesia: slowness of movement
• Postural instability: impaired balance and coordination

These symptoms develop gradually and worsen over time, eventually interfering with walking, speaking, and everyday activities. It is important to note that the presence of one or more of these symptoms does not automatically indicate Parkinson’s disease, as they are shared by other neurological conditions.

Parkinson’s disease is:

• Chronic: it persists over a long period of time and is currently irreversible
• Progressive: it worsens steadily over the years
• Not contagious: it cannot be transmitted from person to person

While some cases have a hereditary component, the vast majority are sporadic, meaning no clear single cause is identified. Current scientific consensus suggests that Parkinson’s disease arises from an interaction between genetic susceptibility and environmental factors.

Parkinson’s disease is the most common form of parkinsonism, a broader umbrella term for a group of conditions that share similar motor symptoms. It is also referred to as primary parkinsonism or idiopathic Parkinson’s disease (the term “idiopathic” denoting a disease with no identified cause). Secondary or atypical parkinsonisms can sometimes be caused by vascular brain changes, medications, or other underlying neurological diseases.

---

Causes

From a neurochemical standpoint, Parkinson’s disease is caused by the progressive degeneration of dopaminergic neurons, primarily in a region of the brain called the substantia nigra. These neurons produce dopamine, a neurotransmitter essential for smooth, coordinated movement. As neurons are lost, dopamine levels fall, and the brain’s ability to control movement becomes increasingly impaired.

Who Is Most Affected?

Parkinson’s disease affects men more often than women, though the reasons for this disparity remain incompletely understood. While it occurs across all geographic regions, several studies have reported higher incidence rates in developed countries. Additional risk factors include:

• Living in rural environments
• Exposure to pesticides or industrial toxins
• Certain occupational exposures

Definite triggers include:

• Head trauma (notably more prevalent among former professional boxers)
• Exposure to environmental toxins
• Cerebral atherosclerosis

Age as a Risk Factor

Age is the most significant risk factor. The average age of onset is 60 years, and incidence increases substantially with advancing age. Approximately 5–10% of patients develop symptoms before the age of 50. These early-onset cases are more likely to have a hereditary basis and to be associated with specific gene mutations.

Genetic Factors

People with one or more close relatives diagnosed with Parkinson’s disease have an elevated risk, though the absolute risk remains modest (2–5% in the absence of a known genetic mutation). Estimates suggest that 15–25% of patients have at least one affected first-degree relative.

Key genes implicated in familial Parkinson’s disease include:

• LRRK2 (leucine-rich repeat kinase 2), the most common cause of autosomal dominant familial Parkinson’s
• SNCA (alpha-synuclein): mutations lead to abnormal protein aggregation
• PINK1 and Parkin, which are associated with autosomal recessive early-onset forms
• GBA (glucocerebrosidase) variants are the most common genetic risk factor for sporadic Parkinson’s

Juvenile Parkinsonism

In very rare cases, parkinsonian symptoms can manifest in individuals under the age of 20, a condition known as juvenile parkinsonism. It is particularly reported in Japan but occurs globally. It typically presents with dystonia and bradykinesia, often responds well to levodopa, and frequently has a familial pattern linked to specific gene mutations.

Environmental Hypothesis

A compelling body of evidence supports the role of environmental triggers. Severe parkinsonism was documented in individuals who used illicit drugs contaminated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a chemical that selectively destroys dopaminergic neurons in the substantia nigra. Similarly, an epidemic of post-encephalitic parkinsonism followed the influenza pandemic of 1918, pointing to viral triggers.

The prevailing hypothesis holds that one or more environmental factors may trigger the disease in genetically predisposed individuals, through mechanisms involving mitochondrial dysfunction, oxidative stress, neuroinflammation, and abnormal protein aggregation (particularly of alpha-synuclein into structures called Lewy bodies).

---

Symptoms

The three cardinal motor symptoms of Parkinson’s disease are:

1. Tremor: involuntary shaking at rest
2. Slowness of movement (bradykinesia)
3. Muscle rigidity and reduced flexibility

These are commonly accompanied by a wide range of other physical and psychological symptoms that evolve over the course of the disease.

Early Symptoms and Disease Progression

The earliest signs of Parkinson’s disease are often subtle and may appear unrelated to one another. They include:

• Mild trembling or shaking
• Difficulty rising from a chair
• Speaking unusually softly or in a monotone
• Handwriting becoming small, slow, or cramped (micrographia)
• Losing one’s train of thought
• Feeling fatigued, irritable, or inexplicably depressed

One particularly important early warning sign is a reduced ability to detect odors (hyposmia) or a complete loss of smell (anosmia). These olfactory changes can precede the classic motor symptoms of Parkinson’s disease by months or even years (source).

Friends and family members are often the first to notice behavioral or physical changes. They may observe:

• A mask-like, expressionless face (hypomimia)
• Reduced or absent arm swing on one side while walking
• An unusual stiffness or slowness in movement

As the disease progresses, tremor typically becomes the symptom that prompts medical consultation, as it begins to interfere with daily activities such as reading, eating, or handling objects.

The Parkinsonian Gait

Many patients develop a distinctive parkinsonian gait characterized by:

• A forward-stooped posture
• Short, shuffling steps with a tendency to accelerate involuntarily (festination)
• Reduced or absent arm swing
• Episodes of “freezing”, sudden and brief inability to initiate movement

Symptoms often begin asymmetrically (on one side of the body), and although they eventually spread to both sides, one side typically remains more severely affected throughout the course of the illness.

The Four Cardinal Motor Symptoms in Detail

• Tremor: The Parkinson’s tremor is characteristically a resting tremor, most prominent when the limb is at rest and diminishing with intentional movement. It has a rhythmic frequency of 4–6 cycles per second and classically presents as a pill-rolling motion of the thumb and index finger. It worsens under emotional stress and disappears during sleep.

• Rigidity: Muscle stiffness resulting from increased resistance to passive movement. Unlike spasticity (which is velocity-dependent), Parkinsonian rigidity is uniform throughout the range of motion and may produce a cogwheel phenomenon (a ratchet-like resistance felt by the examiner). Patients often experience muscle pain, aching, and a sense of weakness.

• Bradykinesia: Slowness of movement is arguably the most disabling symptom, as it affects virtually every motor task. Activities that were once automatic, such as dressing, washing, and turning in bed, become slow, laborious, and exhausting. Fine motor control is particularly impaired.

• Postural Instability: Impaired balance and righting reflexes significantly increase the risk of falls. Patients may develop a flexed, stooped posture with the head bowed and shoulders rounded. Postural instability typically appears in later stages of the disease and does not respond well to levodopa therapy.

Other Symptoms

Beyond the motor hallmarks, Parkinson’s disease involves a broad spectrum of non-motor symptoms that can profoundly affect quality of life. These are increasingly recognized as a core part of the disease, and some precede motor symptoms by years.

• Depression: One of the most frequent non-motor symptoms, occurring in up to 50% of patients. It can appear early in the disease course, even before motor symptoms are evident. It is usually treatable with antidepressant medications.

• Mood and behavioral changes: Anxiety, apathy, social withdrawal, loss of motivation, irritability, and pessimism are common. Some patients develop disorders of impulse control (gambling, hypersexuality) as a side effect of dopamine agonist medications.

• Dysphagia: difficulty swallowing and chewing: In later stages, impaired oropharyngeal muscle function may cause saliva to accumulate, leading to choking and a higher risk of aspiration. This significantly affects nutritional status and respiratory health. Speech therapists and dietitians play a vital role in management.

• Speech changes: Approximately 50% of patients develop hypophonia (softened voice), dysarthria (slurred speech), rapid or monotone delivery, or involuntary repetition of words (palilalia). Speech therapy can help manage these difficulties.

• Urinary and bowel problems: Autonomic dysfunction may cause urinary incontinence or urgency, difficulty voiding, and constipation. Constipation is particularly common and may predate motor symptoms by years. It can be exacerbated by inactivity, poor diet, inadequate hydration, and certain medications.

• Skin problems: Seborrheic dermatitis causing oily skin on the face, scalp, and dandruff, or conversely very dry skin, are related to autonomic nervous system dysregulation. Excessive sweating (hyperhidrosis) is also frequently reported.

• Sleep disorders: Common problems include frequent nocturnal awakenings, vivid dreams, nightmares, daytime somnolence, and REM Sleep Behavior Disorder (RBD). In this condition, patients physically act out their dreams. RBD is now recognized as a major prodromal marker of Parkinson’s disease, often predating motor symptoms by a decade or more.

• Dementia and cognitive impairment: While not universal, many patients develop cognitive changes ranging from mild executive dysfunction to full Parkinson’s disease dementia (PDD), affecting memory, social judgment, language, and reasoning. The drug rivastigmine has shown modest benefits in managing behavioral symptoms in Parkinson’s dementia.

• Orthostatic hypotension: A sudden drop in blood pressure upon standing, causing dizziness and, in severe cases, fainting. It results from degeneration of sympathetic nervous system fibers that regulate heart rate and blood pressure.

• Muscle cramps and dystonia: Rigidity frequently causes painful muscle cramps, especially in the legs and feet. Dystonia, which involves sustained involuntary muscle contractions causing abnormal postures, is often linked to fluctuations in dopamine levels. It can frequently be managed by adjusting the timing and doses of medication.

• Pain: Musculoskeletal pain related to rigidity and abnormal posture is common. Neuropathic pain, arising from central sensitization in the brain, may also occur and is treated with dopaminergic agents, opioids, or antidepressants.

• Fatigue and loss of energy: Profound fatigue is one of the most debilitating non-motor symptoms, worsening toward the end of the day. It may be linked to depression, sleep disorders, muscle overexertion, or akinesia. Regular exercise, adequate sleep hygiene, and pacing of daily activities can help.

• Sexual dysfunction: Erectile dysfunction and reduced libido are reported frequently, stemming from autonomic dysfunction, reduced dopaminergic drive, or as side effects of medications including antidepressants.

---

Diagnosis

The diagnosis of Parkinson’s disease is primarily a clinical process conducted by a neurologist specializing in movement disorders. Despite significant technological advances, no single blood test or imaging study can definitively confirm the diagnosis in its early stages. However, emerging biomarkers are beginning to change this landscape.

Clinical Evaluation

A thorough medical history and neurological examination form the cornerstone of diagnosis. The clinician looks for the cardinal motor features:

• Bradykinesia (mandatory for diagnosis)
• Combined with resting tremor and/or muscular rigidity

Additional assessments include:

• Evaluation of posture and balance
• Observation of facial expression (looking for hypomimia)
• Assessment of gait and arm swing

A key diagnostic tool is the levodopa challenge test: a significant and rapid improvement in motor symptoms following the administration of levodopa strongly supports a diagnosis of idiopathic Parkinson’s disease, as opposed to atypical parkinsonian syndromes (such as Multiple System Atrophy or Progressive Supranuclear Palsy), which respond poorly to levodopa.

The UK Brain Bank Criteria remain widely used for clinical diagnosis and require the presence of bradykinesia plus at least one other cardinal feature, in the absence of exclusion criteria.

Supportive Diagnostic Tests

Imaging and laboratory tests are primarily used to exclude other conditions that can mimic Parkinson’s disease:

• Brain MRI (Magnetic Resonance Imaging): Rules out structural lesions, stroke, normal pressure hydrocephalus, or other pathologies that can produce parkinsonian symptoms. Advanced MRI techniques (e.g., neuromelanin-sensitive imaging, diffusion tensor imaging) can now detect subtle changes in the substantia nigra.

• DaTSCAN (Dopamine Transporter Scintigraphy / SPECT): A nuclear medicine imaging technique that visualizes the density of dopamine transporters in the striatum. In Parkinson’s disease, a characteristic asymmetric reduction in dopamine transporter uptake is observed. DaTSCAN is particularly useful for differentiating Parkinson’s disease from essential tremor, in which the scan is normal.

• Emerging Biomarkers: Alpha-Synuclein Seed Amplification Assay (α-syn SAA) This represents the most significant recent advance in Parkinson’s diagnostics. These highly sensitive assays detect misfolded alpha-synuclein aggregates, the pathological hallmark of Parkinson’s disease, in cerebrospinal fluid or skin biopsies. This detection may occur potentially years before the onset of motor symptoms. As of 2023, α-syn SAA is being integrated into research criteria and is expected to transform early and preclinical diagnosis.

• Autonomic testing: Tilt-table testing, cardiovascular autonomic assessments, and skin biopsy for autonomic nerve fiber density can help differentiate between Parkinson’s disease and other parkinsonian syndromes.

Note: There is currently no validated blood test for Parkinson’s disease for routine clinical use, though research into plasma and CSF biomarkers is advancing rapidly.

---

Treatment and Therapy

The main goals of Parkinson’s disease management are:

1. Controlling symptoms
2. Preserving functional independence
3. Maximizing quality of life

Because the disease follows a unique trajectory in each individual, treatment plans must be highly personalized and regularly reviewed by a multidisciplinary team including neurologists, physiotherapists, speech therapists, dietitians, and mental health professionals.

No treatment currently available has been proven to halt or reverse the neurodegeneration underlying Parkinson’s disease (neuroprotection remains an active area of research). All current therapies are therefore symptomatic.

Pharmacological Treatments

Pharmacological therapy aims to restore or mimic the action of dopamine in the brain.

Levodopa

Levodopa remains the most effective and most widely used drug for Parkinson’s disease, nearly six decades after its introduction. It is converted to dopamine in the brain, effectively replenishing depleted stores.

To prevent peripheral conversion (which causes nausea and other side effects), levodopa is always administered in combination with a decarboxylase inhibitor:

• Carbidopa/levodopa (Sinemet)
• Benserazide/levodopa (Madopar)

Over time, particularly after 5–10 years of use, motor complications may emerge:

• Wearing-off: The effect of each dose shortens, causing predictable return of symptoms before the next dose
• Dyskinesias: Involuntary, often choreiform movements occurring at peak drug effect

Dopamine Agonists

These drugs directly stimulate dopamine receptors and include:

• Pramipexole, ropinirole (oral)
• Rotigotine (transdermal patch)
• Apomorphine (subcutaneous injection, used for acute “off” episodes)

They are often used as initial monotherapy in younger patients to delay the introduction of levodopa and reduce the risk of motor complications. Important side effects include sudden-onset sleep (somnolence), hallucinations in older patients, and impulse control disorders (compulsive gambling, hypersexuality, binge eating).

MAO-B Inhibitors

Monoamine oxidase type B inhibitors, such as rasagiline and selegiline, slow the breakdown of dopamine in the brain. This action prolongs and enhances dopamine’s effect. They are used as initial therapy in mild disease or as adjuncts to levodopa.

COMT Inhibitors

Catechol-O-methyltransferase inhibitors, such as entacapone and opicapone, block the peripheral metabolism of levodopa. This extends its duration of action and smooths out fluctuations. Tolcapone acts both centrally and peripherally but requires liver function monitoring.

Amantadine

Originally developed as an antiviral, amantadine has mild anti-parkinsonian properties and is notably used to manage levodopa-induced dyskinesias in advanced disease.

Advanced Therapies and Surgery

When oral pharmacotherapy can no longer adequately control motor fluctuations, more advanced interventions are considered.

Deep Brain Stimulation (DBS)

DBS is the most established surgical treatment for Parkinson’s disease. It involves the implantation of thin electrodes into specific brain targets, most commonly the subthalamic nucleus (STN) or the globus pallidus internus (GPi), which are then connected to a subcutaneously implanted pulse generator (neurostimulator).

DBS is highly effective for:

• Reducing tremor, rigidity, and motor fluctuations
• Decreasing dyskinesias (when GPi is targeted)
• Improving “on” time

Ideal candidates are patients with levodopa-responsive Parkinson’s disease who are experiencing disabling motor fluctuations or medication-refractory tremor, but who do not have significant cognitive impairment or psychiatric comorbidities.

Continuous Infusion Systems

These devices deliver medication at a stable, continuous rate, minimizing the peaks and troughs associated with oral dosing:

• Subcutaneous apomorphine infusion pump: Apomorphine is a potent dopamine agonist administered continuously via a small pump under the skin. Very effective for controlling motor fluctuations.
• Levodopa-carbidopa intestinal gel (LCIG / Duopa): A gel formulation delivered directly into the small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube. Provides highly stable levodopa levels throughout the day.

MR-guided Focused Ultrasound (MRgFUS)

A non-invasive technique that uses focused beams of ultrasound energy, guided by MRI, to create a precisely targeted lesion in the thalamus (thalamotomy) for the treatment of severe medication-refractory tremor. Unlike DBS, it does not involve implanted hardware, but its effects are currently unilateral (treating one side only).

Lifestyle and Rehabilitation

Physical activity is no longer considered merely supplementary. Instead, it is increasingly recognized as a core component of Parkinson’s disease management. Evidence suggests it may slow functional decline.

Exercise

• Aerobic exercise (walking, cycling, swimming): improves cardiovascular fitness, mood, and overall motor function
• Resistance training: maintains muscle mass and strength
• Balance and flexibility training: critical for fall prevention
• Tango dancing and Tai Chi: specifically shown to improve balance, gait, and quality of life in Parkinson’s patients
• Boxing-inspired training programs (e.g., Rock Steady Boxing): gaining popularity for their beneficial effects on coordination and confidence

Physiotherapy

Physiotherapists design individualized programs targeting gait, balance, posture, and transfer techniques. They also train patients in cueing strategies, which involve using visual cues like floor markings or auditory cues such as rhythmic beats to overcome freezing of gait.

Speech and Language Therapy

The Lee Silverman Voice Treatment (LSVT LOUD) is a validated, intensive speech therapy program that effectively improves vocal loudness and intelligibility in Parkinson’s disease. Therapists also address swallowing dysfunction, helping to reduce aspiration risk.

Nutritional Support

A balanced diet rich in fiber helps manage constipation. Patients on levodopa should be aware that high-protein meals can interfere with drug absorption. Working with a registered dietitian is advisable, particularly in later stages when swallowing difficulties arise.

Psychological Support

Living with a chronic, progressive neurological illness is profoundly challenging. Psychological support, cognitive-behavioral therapy, and support groups (both in person and online) play an important role in managing depression, anxiety, and social isolation for both patients and their caregivers.

---

Parkinson’s Disease and Life Expectancy

One of the most frequently asked questions, from both patients and people searching online, is whether Parkinson’s disease is fatal. The honest and medically accurate answer is nuanced.

Parkinson’s disease is not directly fatal in itself. It is a chronic, progressive condition, and patients will live with the disease, but Parkinson’s disease itself is not typically the direct cause of death.

With modern treatment and timely diagnosis, the average life expectancy of a person with Parkinson’s disease is broadly similar to that of the general population. However, in advanced stages of the disease, serious complications can arise that significantly increase mortality risk:

• Aspiration pneumonia: The most common cause of death in advanced Parkinson’s. Swallowing difficulties (dysphagia) lead to the inhalation of food or liquid into the lungs, causing aspiration pneumonia and, potentially, pneumonia.
• Falls and related injuries: Severe postural instability and balance impairment lead to frequent falls, which can result in serious fractures (particularly hip fractures) and fatal complications.
• Immobility-related complications: Deep vein thrombosis, pressure ulcers, and generalized debilitation in the late stages.

Disease progression varies considerably between individuals. While symptoms may take 20 years or more to become severely disabling in some patients, others experience a more rapid course. There is currently no reliable way to predict how the disease will evolve in any given individual.

Key takeaway: Parkinson’s disease is not a death sentence. With appropriate medical management, rehabilitation, and a strong support network, many patients maintain a meaningful quality of life for years or even decades after diagnosis.

---

Sources and Bibliography

• National Institute of Neurological Disorders and Stroke (NINDS). Parkinson’s Disease. Updated 2023.
• American Parkinson Disease Association (APDA). Symptoms of Parkinson’s Disease.
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2015;30(12):1591–1601. DOI: 10.1002/mds.26424
• Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397(10291):2284–2303. DOI: 10.1016/S0140-6736(21)00218-X
• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature Reviews Disease Primers. 2017;3:17013. DOI: 10.1038/nrdp.2017.13
• Kalia LV, Lang AE. Parkinson’s disease. The Lancet. 2015;386(9996):896–912.
• Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. Nature Reviews Neurology. 2017;13(2):119–126.
• Parkinson’s Foundation. Understanding Parkinson’s.
• Mayo Clinic. Parkinson’s Disease: Symptoms and Causes.
• European Academy of Neurology / Movement Disorder Society-European Section guidelines on Parkinson’s disease management. 2023.